James Paul Lang insider trades: OptimizeRx (OPRX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | OPRX | ↑ Buy | 321,408 | $7.60 | $2.4M | Direct | Mar 19, 2025 (5d) |
| Aug 19, 2022 | OPRX | ↑ Buy | 6,000 | $16.45 | $99K | Direct | Aug 23, 2022 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OPRX insiders
Open-market trades in the last 12 months
About James Paul Lang's insider trades
James Paul Lang is a director at OptimizeRx (OPRX). Since Aug 19, 2022, James has reported 2 open-market purchases worth $2.5M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (32 filings), option exercises (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OPRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.